# US 8,280,643 B2 · Crystal structure of Staphylococcus aureus clumping factor A in complex with fibrinogen derived peptide and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,280,643 B2
- Document ID: US8280643B2
- Status: Granted
- Kind: B2
- Application number: 12/459,327
- Filed: 2009-06-30
- Published: 2010-01-21
- Granted: 2012-10-02
- Earliest claimed: 2008-06-30
- Assignees: The Texas A&M University System
- Inventors: Magnus Hook; Ya-Ping Ko; Emanuel Smeds; Vannakambadi K. Ganesh
- Web page: https://patentgrep.com/patent/US8280643B2

## CPC

- C07K 14/75: Fibrinogen
- A61K 38/363: {Fibrinogen}
- A61P 31/04: Antibacterial agents
- C07K 14/31: from Staphylococcus (G)
- C07K 16/1271: Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
- C07K 16/18: against material from animals or humans
- C07K 16/36: against blood coagulation factors
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/035: containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- G01N 2333/31: from Staphylococcus (G)
- G01N 2333/75: Fibrin; Fibrinogen
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides a method for determining the structure of a microbial surface components recognizing adhesive matrix molecule in complex with fibrinogen, by providing a ClfA complexed with a fibrinogen gamma-peptide; determining a ClfA binding region of the fibrinogen gamma-peptide; determining one or more critical amino acid residues in the ClfA binding region of a native fibrinogen gamma-peptide that is critical for a ClfA:fibrinogen gamma-peptide interaction; determining one or more amino acid residues of the ClfA that binds to the ClfA binding region of the native fibrinogen gamma-peptide; modeling the structure of the ClfA binding region; determining the structure of the ClfA in complex with the :fibrinogen gamma-peptide interaction; and identifying one or more potential agent(s) that inhibit the ClfA:fibrinogen gamma-peptide interaction without affecting binding of other proteins to the fibrinogen gamma-peptide.

## Claims

### Claim 1

A method for determining the structure of a microbial surface components recognizing adhesive matrix molecule in complex with fibrinogen, comprising the steps of:
providing a Clumping factor A ClfA complexed with a fibrinogen gamma-peptide;
determining a ClfA binding region of the fibrinogen gamma-peptide;
determining one or more critical amino acid residues in the ClfA binding region of a native fibrinogen gamma-peptide that is critical for a ClfA:fibrinogen gamma-peptide interaction;
determining one or more amino acid residues of the ClfA that binds to the ClfA binding region of the native fibrinogen gamma-peptide;
modeling the structure of the ClfA binding region;
performing computational modeling of the ClfA sequence that binds to the ClfA binding region of native fibrinogen, thereby determining the structure of the ClfA:fibrinogen gamma-peptide interaction; and
identifying one or more potential agents that inhibit the ClfA:fibrinogen gamma-peptide interaction without affecting binding of other proteins to the fibrinogen gamma-peptide.

### Claim 2 (depends on 1)

The method of claim 1, further comprising identifying one or more potential agents with at least one different amino acid from the native fibrinogen that inhibit ClfA:fibrinogen gamma-peptide interaction without affecting binding of other proteins to fibrinogen gamma-peptide.

### Claim 3 (depends on 2)

The method of claim 2, wherein the one or more potential agents comprise an amino acid sequence of the ClfA binding region on fibrinogen gamma-peptide that differs from the fibrinogen gamma-peptide by at least one amino acid and differs from the ClfA by at least one amino acid.

### Claim 4 (depends on 1)

The method of claim 1, further comprising the steps of
synthesizing one or more control peptides that comprise the native fibrinogen gamma-peptide sequence that binds the ClfA;
synthesizing one or more substituted peptides that differ from the one or more control peptides by one or more amino acid residues; and
comparing binding of the ClfA to native fibrinogen gamma-peptide in the presence of the one or more control peptides or in the presence of the one or more substituted peptides, wherein less potent inhibition of the ClfA binding to the native fibrinogen gamma-peptide in the presence of the substituted peptide compared to the one or more control peptides indicates that the amino acid residues that were substituted are less important for the ClfA:fibrinogen gamma-peptide interaction, and wherein extensive inhibition of the ClfA binding to native fibrinogen gamma-peptide in the presence of the one or more substituted peptides compared to the one or more control peptides indicates that the amino acid residue that were substituted are critical for the ClfA:fibrinogen gamma-peptide interaction to determine the one or more critical amino acid residues.

### Claim 5 (depends on 1)

The method of claim 1, wherein the amino acid residue in the ClfA is determined by comparing the stability of a native ClfA:fibrinogen gamma-peptide complex with the stability of a mutated ClfA:fibrinogen gamma-peptide complex, wherein said fibrinogen gamma-peptide in the complex comprises a peptide derived from the ClfA binding region of native fibrinogen gamma-peptide.

### Claim 6 (depends on 1)

The method of claim 1, wherein said ClfA is present on the surface of Staphylococcus aureus, Staphylococcus lugdunensis, or Staphylococcus epidermidis.

### Claim 7 (depends on 1)

The method of claim 1, wherein the native fibrinogen comprises a K406A peptide, a D410A peptide, or a K406A and D410A peptide.

### Claim 8 (depends on 1)

The method of claim 1, wherein the other proteins to the fibrinogen gamma-peptide comprises integrin αIIbβ3.
